TUCSON, AZ / ACCESSWIRE / September 21, 2022 / Aqualung Therapeutics, an immunotherapeutics biotech company with an anti-inflammatory and anti-fibrosis therapeutic platform for serious unchecked inflammatory and fibrotic disorders, has been awarded two 3-year NIH FAST-TRACK AWARDS [R42DK135208; R42HL160422) to support development of ALT-100, a humanized monoclonal antibody (mAb) therapy for the chronic indications of Pulmonary Arterial Hypertension (PAH) and Inflammatory Bowel Disease (IBD). The ALT-100 mAb targets the inflammation-inducing damage-associated molecular pattern protein eNAMPT, and is currently in Phase 1A human safety trials.
Author Archive: AZBioPEERS Team
Arizona Alzheimer’s Disease Research Center (ADRC) Development Grant: Request for Proposals
APPLICATION RECEIPT DATE:
Optional Pre-proposal Deadline: September 30, 2022 Full Application Deadline: October 28, 2022 Anticipated Start Date: July 1, 2023
PURPOSE: The Arizona Alzheimer’s Disease Research Center (ADRC) invites applications for development grant proposal studies to support basic or clinical biomedical, translational, epidemiological, caregiving, educational, or behavioral studies in AD, ADRD or brain aging research. Developmental projects are intended to help establish the basis for applying for further research funding and further development of the applicant’s career in these areas of research.
The Fundación Instituto Valenciano de Oncología Leverages HTG Technology for Breast Cancer Laboratory-Developed Test
TUCSON, Ariz., Sept. 20, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that the Fundación Instituto Valenciano de Oncología, located in Valencia, Spain (IVO), with its partners, the Fundación Pública Andaluza Progreso y Salud (FPS) and the Centro de Investigación Biomédica en Red (CIBER), have developed a laboratory-developed test (LDT) (the MPD Test) for the assessment of breast cancer recurrence based on their use of the HTG EdgeSeq™ technology.Continue reading
App Created by MD/PhD Student Provides Accessible Training Resource for Adaptive Sports
“I did some research and saw there were almost zero apps specifically designed for people who use wheelchairs,” Conner said.Continue reading
New UArizona center to support Native American entrepreneurs
The University of Arizona has received a five-year, $500,000 matching grant from the U.S. Economic Development Administration to establish a new center to support economic growth in tribal communities in Arizona.
Decreased PEMT Gene Expression In The Liver Is Linked To Severity In Nonalcoholic Fatty Liver Disease
PHOENIX, Ariz. — August 22, 2022 — Nonalcoholic fatty liver disease (NAFLD) is both increasingly common and potentially deadly; yet its causes remain poorly understood. Now, a collaborative team of researchers at the Translational Genomics Research Institute (TGen), part of City of Hope, and Temple University has uncovered a link between decreases in an enzyme that makes choline in the liver —an essential nutrient for humans— and severity of NAFLD.
UArizona R. Ken Coit College of Pharmacy Ranked No. 5 by American Association of Colleges of Pharmacy
More than $20 million in National Institutes of Health (NIH) grants and contracts in fiscal year 2021 propelled the University of Arizona R. Ken Coit College of Pharmacy to No. 5 in American Association of Colleges of Pharmacy (AACP) rankings.
Skysong Innovations seeks ASU faculty startups for its 4th annual Startup Challenge
Up to $50,000 in seed investments is available for faculty who recently started a company to commercialize Arizona State University-owned inventions during the fourth annual Skysong Innovations Startup Challenge.
Dr. John Galgiani Wins Inaugural UArizona Director’s Award
John Galgiani, MD, director of the University of Arizona Valley Fever Center for Excellence and professor in the UArizona College of Medicine – Tucson, was honored as the inaugural recipient of the Distinguished Director’s Award and one of 25 faculty members singled out for excellence in teaching, scholarship and outreach.
TGEN Names Kevin Campbell Chief Information Officer
Phoenix, AZ — Aug. 17, 2022 — The Translational Genomics Research Institute (TGen), part of City of Hope, today announced that industry veteran Kevin Campbell has been appointed the Institute’s Chief Information Officer.